Catheter Connections receives U.S. patent for DualCap IV disinfection technology

Published on January 18, 2013 at 7:40 AM · No Comments

Catheter Connections, a start-up company co-founded by nurses seeking to reduce deadly hospital-acquired bloodstream infections, announced today the issuance of U.S. Patent Number 8,343,112. This is the sixth patent issued to the Company in a portfolio that broadly covers its DualCap® technology for disinfecting IV connectors ─ technology which helps protect hospital patients from deadly infections.

The Company has the only granted U.S. patents for protecting and disinfecting "male luer" connectors, which are the connectors used to connect IV tubing lines to IV catheters. In its mission to save patient lives, Catheter Connections conceived, developed, manufactures and markets the DualCap System™, which includes DualCap® ─ the first 510(k) cleared medical device that disinfects male luer connectors, killing the microorganisms known to cause bloodstream infections and protecting the connectors from contamination.

The Company has pending lawsuits against Ivera Medical Corporation ("Ivera") in the U.S. District Court of Utah, Central Division, where it accuses Ivera of infringing some of its patents, unfair competition, deceptive practices and false advertising related to the marketing of Ivera's male luer disinfectant cap.

Ivera has a history of filing suits against its competitors ─ Excelsior Medical Corporation, Hospira, Inc., and Catheter Connections ─ and has patent infringement suits pending against each in the U.S. District Court for the Southern District of California. While the California Court recently denied a request to stay these suits without prejudice to filing the request again, the stay has no impact upon the pending inter partes reexaminations in which the United States Patent and Trademark Office ("USPTO") has rejected each of Ivera's patent claims for which reexamination was requested. The Court has not examined the merits of Ivera's suits and by denying the stay it did not make any comment about whether the USPTO will invalidate the contested patent claims.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post